Novo Nordisk cuts Ozempic price for uninsured Canadians as Apotex ships generic semaglutide

Novo Nordisk has cut the price of Ozempic for uninsured Canadians through its savings card as Apotex began shipping generic semaglutide and Dr. Reddy's expanded distribution, a development reported September 13, 2026 ^[1]. Health Canada has approved three of nine generic semaglutide products filed in the country ^[1].

The Ozempic savings card was introduced on August 17, 2026, and aligns the brand's price with generic semaglutide for uninsured Canadians. It excludes Quebec and is distributed through Rexall pharmacies ^[1]. On August 21, 2026, Rexall and Novo Nordisk Canada launched Novo Nordisk Care Rx home delivery for Ozempic, Wegovy and Rybelsus across all provinces and territories except Quebec ^[1].

Dr. Reddy's received Health Canada authorization for its generic semaglutide on April 28, 2026, and eight additional generic semaglutide submissions remain under review ^[1]. Apotex is offering full SKU parity with Ozempic, meaning the same product formats and strengths ^[1]. As of August 6, 2026, the Canadian Generic Pharmaceutical Association said more than 500 generic submissions were sitting at Health Canada, with more than 100 backlogged, and seven generic semaglutide files still awaiting decisions ^[1]. Two other products, Aspen-Semaglutide and Sevmia, were listed as approved but not marketed as of July 28, 2026 ^[1].

Canada's pCPA pricing tiers set generic semaglutide at 75% to 85% of the brand price for the first entrant, dropping to 35% of brand once three or more generics reach the market ^[1]. That second step equals a 65% cut from list price, and Canadian benefits plans have been told to expect it when a third generic launches; Sandoz is targeting the third quarter of 2026, while Aspen is going Canada-first ^[1]. Sandoz has estimated its proposed generic tirzepatide at $200 to $400 per month ^[1].

Novo Nordisk has projected a 5% to 13% revenue decline in 2026, while Eli Lilly forecast $80 billion to $83 billion ^[1]. Eli Lilly reported $9.94 billion in second-quarter Mounjaro sales, and its executives flagged Canadian generic supply constraints while Novo Nordisk executives defended volumes through savings cards ^[1]. Novo Nordisk stopped paying a C$250 annual patent maintenance fee in 2018, a decision that ultimately let generic semaglutide reach Canadian pharmacies in 2026 ^[1]. Patent expert Tahir Amin of I-MAK told the BBC that Novo Nordisk could have extended its Canadian Ozempic patent to 2028 but did not renew it ^[1]. Novo Nordisk CEO Mike Doustdar has called the oral Wegovy pill a "must-win" as Canadian generics ship; oral Wegovy won US approval in December 2025 ^[1].

Why it matters for patients

For uninsured Canadians filling Ozempic, the savings card narrows the gap between the brand and its generics. The card is not available in Quebec, where provincial rules apply ^[1]. Cost is only part of the picture: Health Canada issued advisory RA-81518 on September 11, 2026, warning about unauthorized and counterfeit GLP-1 products sold by retailers and online, and it directs buyers to licensed pharmacies ^[1].

For US patients, no equivalent price match has been reported. The savings card, the generic approvals and the tiered pricing described here apply in Canada ^[1]. Whether a GLP-1 manufacturer would match generic prices in the United States, and when generic semaglutide might reach US pharmacies, has not been disclosed ^[1]. US coverage decisions, list prices and pharmacy availability are set separately from Canada's, and no change to US pricing tied to these Canadian shipments has been reported ^[1].

What happens next

Eight additional generic semaglutide files remain under Health Canada review, and the lower pCPA price tier is tied to a third generic reaching the market ^[1]. Sandoz has said it is targeting the third quarter of 2026, and Aspen is going Canada-first ^[1]. Novo Nordisk's guidance of a 5% to 13% revenue decline covers the full 2026 year ^[1].